Michèle Barzach
Corporate Officer/Principal presso International AIDS Vaccine Initiative, Inc.
Posizioni attive di Michèle Barzach
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Corporate Officer/Principal | 30/11/2010 | - |
Storia della carriera di Michèle Barzach
Precedenti posizioni note di Michèle Barzach
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GSK PLC | Direttore/Membro del Consiglio | 01/01/1997 | 17/05/2004 |
| Independent Dir/Board Member | 01/01/1997 | 17/05/2004 |
Statistiche
Distribuzione geografica
| Regno Unito | 2 |
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GSK PLC | Health Technology |
| Aziende private | 1 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Michèle Barzach
- Esperienza